NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $68.09 +1.25 (+1.87%) As of 11:45 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nektar Therapeutics Stock (NASDAQ:NKTR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nektar Therapeutics alerts:Sign Up Key Stats Today's Range$66.10▼$68.0050-Day Range$64.84▼$76.4852-Week Range$33.40▼$109.00Volume188,449 shsAverage Volume1.00 million shsMarket Capitalization$2.32 billionP/E RatioN/ADividend YieldN/APrice Target$141.50Consensus RatingModerate Buy Company Overview Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that harness the body’s immune system to treat cancer and autoimmune and inflammatory diseases. The company’s research is centered on cytokine biology, immune-cell regulation and its proprietary polymer-conjugation technologies, which are designed to modify therapeutic compounds and potentially improve their duration, delivery or tolerability. Nektar’s pipeline has included investigational therapies such as rezpegaldesleukin, an immune-modulating treatment being studied for autoimmune and inflammatory conditions. The company has also developed drug candidates for oncology and has historically advanced products through collaborations with larger pharmaceutical companies. Its technology has contributed to partnered and approved medicines, including the opioid-induced constipation treatment Movantik, which was developed with AstraZeneca. Founded in 1990 and headquartered in San Francisco, California, Nektar has worked with pharmaceutical partners and conducted development activities across international markets. Howard W. Robin has served as the company’s president and chief executive officer for many years. Nektar’s business is primarily focused on research and clinical development, with commercialization and distribution of partnered products generally handled through collaboration agreements.AI Generated. May Contain Errors. Read More Nektar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreNKTR MarketRank™: Nektar Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 431st out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialNektar Therapeutics has a consensus price target of $141.50, representing about 109.3% upside from its current price of $67.59.Amount of Analyst CoverageNektar Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nektar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nektar Therapeutics are expected to decrease in the coming year, from ($8.28) to ($11.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 15.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.23% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 11.45, which indicates bearish sentiment.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 1.63%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.11 News SentimentNektar Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Nektar Therapeutics this week, compared to 10 articles on an average week.Search Interest6 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $441,146.00 in company stock.Percentage Held by Insiders2.50% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTR Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Eli Lilly & Co (LLY)September 18, 2026 | theglobeandmail.comNektar’s Rezpeg Trial Completion Adds a New Catalyst in Alopecia AreataSeptember 18, 2026 | tipranks.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 22 at 1:00 AM | Paradigm Press (Ad)BTIG Research Reaffirms Buy Rating for Nektar Therapeutics (NASDAQ:NKTR)September 18, 2026 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 11, 2026 | americanbankingnews.comBTIG Research Reaffirms "Buy" Rating for Nektar Therapeutics (NASDAQ:NKTR)September 11, 2026 | americanbankingnews.comNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 28, 2026 | prnewswire.comNektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year TestAugust 27, 2026 | finance.yahoo.comSee More Headlines NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $42.28 at the start of the year. Since then, NKTR shares have increased by 59.9% and is now trading at $67.5920. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.74. The biopharmaceutical company earned $10.13 million during the quarter, compared to analysts' expectations of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative trailing twelve-month return on equity of 37.87%. Read the conference call transcript. When did Nektar Therapeutics' stock split? Shares of Nektar Therapeutics reverse split before market open on Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Nektar Therapeutics' major shareholders? Top institutional shareholders of Nektar Therapeutics include Braidwell LP (1.39%), Bank of New York Mellon Corp (0.28%), Readystate Asset Management LP (0.25%) and California State Teachers Retirement System (0.10%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Robert Chess and Jonathan Zalevsky. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol Myers Squibb (BMY), Netflix (NFLX) and ExxonMobil (XOM). Company Calendar Last Earnings8/13/2026Today9/22/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NKTR's financial health is in the Green zone, according to TradeSmith. NKTR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NKTR CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees63Year Founded1990Price Target and Rating Average Price Target for Nektar Therapeutics$141.50 High Price Target$192.00 Low Price Target$65.00 Potential Upside/Downside+113.7%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($6.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$164.08 million Net Margins-287.84% Pretax Margin-280.48% Return on Equity-37.87% Return on Assets-25.67% Debt Debt-to-Equity RatioN/A Current Ratio10.42 Quick Ratio10.42 Sales & Book Value Annual Sales$55.23 million Price / Sales40.94 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book15.02Miscellaneous Outstanding Shares34,140,000Free Float33,289,000Market Cap$2.26 billion OptionableOptionable Beta1.14 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NKTR) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | SponsoredThe Shiller CAPE ratio now sits above 41. Before the 1929 crash, it was 32.6.The Shiller CAPE ratio now sits above 41 a level seen only once before, near the peak of the dot-com bubble. B...USA Capital Gold | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredInside Nevada's 60 Million Ounce Gold CorridorBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTR Stock Alerts